Compounded Tirzepatide
from $232/moon the 12-month plan
GLP-1 prescription therapy for weight loss, reviewed by a licensed provider.
Compare plan lengths
$299/mo × 12
$232/mo
$2,784 charged once your prescription is approved · you save $804
Check your eligibilityA licensed provider reviews every intake before treatment is prescribed.
How Compounded Tirzepatide works
We would rather you understand the medicine than take our word for it.
It mimics two hormones you already make
After a meal your gut releases incretin hormones — GLP-1 and GIP — that tell the pancreas, the stomach and the brain that food has arrived. Tirzepatide activates both of those receptors and is built to last about a week, so the signal that normally fades in minutes stays on between doses.
Coskun et al., Molecular Metabolism, 2018 — discovery and mechanism of tirzepatide
It slows how fast the stomach empties
Food leaves the stomach more gradually, so a meal keeps you comfortably full for longer instead of spiking and crashing. In a controlled study, tirzepatide delayed gastric emptying much as long-acting GLP-1 medicines do, with the effect strongest in the first weeks and easing as the body adjusts.
It turns down appetite signalling
Acting on appetite centres in the brain, it eases hunger and the constant pull of “food noise”, so smaller portions feel like enough. In a controlled study, people on tirzepatide ate less at a free-choice meal and reported lower appetite than on placebo.
Explore results reported in clinical trials
Adjust the starting weight to see a published study average in pounds. Not a prediction of your result.
Trial-average loss for your starting weight
47 lbs
Trial average · Tirzepatide
Your estimated BMI
31.9
Thoughtful care in four clear steps
Medical intake
Tell us about your health history, current medications, goals, and prior treatment. This is a medical screening, not a product order.
Clinical review
A licensed clinician in your state independently decides whether treatment is appropriate. A prescription is not guaranteed.
Medication delivery
If prescribed, a licensed pharmacy prepares your medication and ships it in discreet packaging. Compounded medications are not FDA-approved.
Ongoing care
Use your portal for check-ins, dose questions, side effects, refills, and treatment changes. Your clinician can adjust or stop treatment based on your health and response.
The expanding universe of GLP-1 therapies.
Price points vary, effects differ, and the science keeps moving. Here is how the class compares — including the molecules we do not dispense.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist | Triple GLP-1 / GIP / glucagon agonist |
| Average loss in trials | 14.9% at 68 wks | 22.5% at 72 wks | 24.2% at 48 wks · phase 2 |
| Dosing | Once weekly, subcutaneous | Once weekly, subcutaneous | Not established outside trials |
| Common side effects | Nausea, constipation, diarrhea, fatigue — most often during dose increases | Nausea, diarrhea, vomiting, constipation — most often during dose increases | Gastrointestinal effects reported in trials |
| Regulatory status | Compounded under 503A | Compounded under 503A | Investigational — not available |
| Starting price | from $152/mo 12-mo plan | from $232/mo 12-mo plan | — |
| View Semaglutide | Check your eligibility | Research only — not FDA-approved and not offered by Halwel. Read the explainer |
What changes
The outcomes measured in trials, each with its source.
15–21% average weight loss
SURMOUNT-1 included 2,539 adults with obesity or overweight. After 72 weeks, average weight loss with tirzepatide ranged from 15% to 21%, depending on dose, compared with 3% with placebo.
What to keep in mind: Results vary, and weight regain is common after treatment stops.
SURMOUNT-1, New England Journal of Medicine, 202220% lower cardiovascular risk
SELECT followed 17,604 adults with overweight or obesity who already had cardiovascular disease. Heart attack, stroke, or cardiovascular death occurred in 6.5% of the semaglutide group and 8.0% of the placebo group — a 20% relative reduction.
What to keep in mind: This study involved people who already had cardiovascular disease. It does not establish the same benefit for everyone taking semaglutide.
SELECT, New England Journal of Medicine, 2023Lower progression to type 2 diabetes
A three-year extension of SURMOUNT-1 followed adults with obesity and prediabetes. Type 2 diabetes developed in 1.3% of those taking tirzepatide and 13.3% of those taking placebo while treatment continued.
What to keep in mind: This finding applies to people who already had prediabetes. The difference became smaller after treatment stopped.
SURMOUNT-1 three-year results, New England Journal of Medicine, 2024Less hunger and fewer cravings
A 12-week study followed 30 adults with obesity. People taking semaglutide ate 24% less at a test meal and reported less hunger and fewer cravings than people taking placebo.
What to keep in mind: This was a small, short study. Appetite changes vary from person to person.
Blundell et al., Diabetes, Obesity and Metabolism, 2017Better physical functioning
STEP 1 included 1,961 adults with overweight or obesity. After 68 weeks, people taking semaglutide 2.4 mg reported greater improvement on a physical-functioning questionnaire than people taking placebo.
What to keep in mind: This was a patient-reported measure, not a direct test of strength, fitness, or energy.
STEP 1, New England Journal of Medicine, 2021Fewer sleep-apnea events
SURMOUNT-OSA studied adults with obesity and moderate-to-severe obstructive sleep apnea for 52 weeks. Tirzepatide reduced breathing interruptions by about 25 to 29 events per hour, compared with about 5 per hour with placebo.
What to keep in mind: This result applies to people diagnosed with moderate-to-severe obstructive sleep apnea.
SURMOUNT-OSA, New England Journal of Medicine, 2024Compounded Tirzepatide questions
What patients ask most before starting. If yours isn't here, your clinician answers it during review.
Compounded Tirzepatide is a once-weekly subcutaneous injection you give yourself at home with a fine, pre-measured needle — most patients describe it as quick and nearly painless. Your kit arrives with everything you need, and your care team walks you through your first dose.
The most common effects are mild digestive symptoms — nausea, constipation, or reflux — usually early on and easing as your body adjusts. Starting at a low dose and stepping up gradually (titration) keeps them manageable for most people. Serious reactions are uncommon; your provider reviews your history before prescribing and stays available if anything comes up.
If a licensed provider decides this treatment isn't right for you, you won't pay for medication you don't receive. Where appropriate, your provider will suggest a safer alternative or a next step.
No insurance is needed. Compounded Tirzepatide is a flat cash price that includes your medication, provider consultations, and shipping — no membership fees. It's HSA/FSA eligible, so you can often pay with pre-tax dollars.
When you’re ready, begin with a short medical intake.
A licensed clinician will review your health and decide whether treatment is appropriate.
